Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-445-5704
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.46 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date6/5/2019 (Estimated)
OptionableNot Optionable
Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions
What is Xeris Pharmaceuticals' stock symbol?
Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."
How were Xeris Pharmaceuticals' earnings last quarter?
Xeris Pharmaceuticals Inc (NASDAQ:XERS) issued its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.04. The business had revenue of $0.80 million for the quarter, compared to analysts' expectations of $0.10 million. View Xeris Pharmaceuticals' Earnings History.
When is Xeris Pharmaceuticals' next earnings date?
What price target have analysts set for XERS?
4 brokerages have issued 12-month price targets for Xeris Pharmaceuticals' shares. Their predictions range from $23.00 to $27.00. On average, they expect Xeris Pharmaceuticals' stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 155.2% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.
What is the consensus analysts' recommendation for Xeris Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.
What are Wall Street analysts saying about Xeris Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019)
- 2. Mizuho analysts commented, "We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share." (12/4/2018)
Has Xeris Pharmaceuticals been receiving favorable news coverage?
Headlines about XERS stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
Are investors shorting Xeris Pharmaceuticals?
Xeris Pharmaceuticals saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 1,294,780 shares, an increase of 38.7% from the March 15th total of 933,515 shares. Based on an average daily volume of 276,154 shares, the short-interest ratio is presently 4.7 days. Currently, 5.7% of the company's stock are sold short. View Xeris Pharmaceuticals' Current Options Chain.
Who are some of Xeris Pharmaceuticals' key competitors?
Some companies that are related to Xeris Pharmaceuticals include Radius Health (RDUS), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Omeros (OMER), Deciphera Pharmaceuticals (DCPH), Kiniksa Pharmaceuticals (KNSA), Y-mAbs Therapeutics (YMAB), Rhythm Pharmaceuticals (RYTM), Vanda Pharmaceuticals (VNDA), Alder Biopharmaceuticals (ALDR), Ra Pharmaceuticals (RARX), Eidos Therapeutics (EIDX), Advanz Pharma (CXRXF), Homology Medicines (FIXX) and Retrophin (RTRX).
What other stocks do shareholders of Xeris Pharmaceuticals own?
Who are Xeris Pharmaceuticals' key executives?
Xeris Pharmaceuticals' management team includes the folowing people:
- Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
- Mr. John P. Shannon, Exec. VP & COO (Age 57)
- Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
- Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
- Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
When did Xeris Pharmaceuticals IPO?
(XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.
How do I buy shares of Xeris Pharmaceuticals?
Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xeris Pharmaceuticals' stock price today?
One share of XERS stock can currently be purchased for approximately $9.60.
How big of a company is Xeris Pharmaceuticals?
Xeris Pharmaceuticals has a market capitalization of $258.60 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis.
What is Xeris Pharmaceuticals' official website?
How can I contact Xeris Pharmaceuticals?
Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]
MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
